Neuroimaging of dementia in 2013: What radiologists need to know

European Radiology

Volumn 23, Issue 12, 2013, Pages 3393-3404

  Haller, Sven ^a   Garibotto, Valentina ^b   Kövari, Enikö ^a   Bouras, Constantin ^a   Xekardaki, Aikaterini ^a   Rodriguez, Cristelle ^a   Lazarczyk, Maciej Jakub ^a   Giannakopoulos, Panteleimon ^a   Lovblad, Karl Olof ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Alzheimer; Cognitive decline; Dementia; Frontal dementia; Fronto temporal lobar degeneration; MCI

Indexed keywords

AMYLOID; CARBON 11; FLUORODEOXYGLUCOSE F 18; IOFLUPANE I 123; NEUROTRANSMITTER; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX ATROPHY; BRAIN HEMORRHAGE; BRAIN METABOLISM; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG UPTAKE; FRONTOTEMPORAL DEMENTIA; HUMAN; IMAGE ANALYSIS; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROIMAGING; NONHUMAN; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGIST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHITE MATTER LESION;

AGED; AGING; ALZHEIMER DISEASE; ATROPHY; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; CEREBRAL CORTEX; COGNITION DISORDERS; DEMENTIA; DEMENTIA, VASCULAR; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IRON; LEWY BODIES; MAGNETIC RESONANCE IMAGING; MALE; NERVE FIBERS, MYELINATED; NEUROIMAGING; REFERENCE VALUES; TAU PROTEINS;

EID: 84890562531     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-013-2957-0     Document Type: Article

References (103)

1. Lazarczyk MJ, Hof PR, Bouras C et al (2012) Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med 10:127
2. Chetelat G, Desgranges B, Landeau B et al (2008) Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 131:60-71
3. Lim SM, Katsifis A, Villemagne VL et al (2009) The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 50:1638-1645
4. McKeith I, O'Brien J, Walker Z et al (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6:305-313
5. Rohrer JD (2012) Structural brain imaging in frontotemporal dementia. Biochim Biophys Acta 1822:325-332
6. Gorno-Tempini ML, Dronkers NF, Rankin KP et al (2004) Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 55:335-346
7. Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006-1014
8. Rohrer JD, Ridgway GR, Crutch SJ et al (2010) Progressive logopenic/phonological aphasia: erosion of the language network. NeuroImage 49:984-993
9. Rabinovici GD, Jagust WJ, Furst AJ et al (2008) Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 64:388-401
10. Lindberg O, Ostberg P, Zandbelt BB et al (2009) Cortical morphometric subclassification of frontotemporal lobar degeneration. AJNR Am J Neuroradiol 30:1233-1239
11. Groschel K, Kastrup A, Litvan I et al (2006) Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology 66:949-950
12. Quattrone A, Nicoletti G, Messina D et al (2008) MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 246:214-221
13. Hayflick SJ, Hartman M, Coryell J et al (2006) Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 27:1230-1233
14. Garde E, Mortensen EL, Krabbe K et al (2000) Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet 356:628-634
15. Ylikoski A, Erkinjuntti T, Raininko R et al (1995) White matter hyperintensities on MRI in the neurologically nondiseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke 26:1171-1177
16. Debette S, Markus HS (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 341:c3666
17. Inzitari D, Simoni M, Pracucci G et al (2007) Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch Intern Med 167:81-88
18. Murray AD, Staff RT, McNeil CJ et al (2011) The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases. Brain 134:3687-3696
19. Young VG, Halliday GM, Kril JJ (2008) Neuropathologic correlates of white matter hyperintensities. Neurology 71:804-811
20. Gouw AA, Seewann A, van der Flier WM et al (2011) Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 82:126-135
21. Pantoni L, Garcia JH (1997) Pathogenesis of leukoaraiosis: a review. Stroke 28:652-659
22. Fazekas F, Kleinert R, Offenbacher H et al (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 43:1683-1689
23. Grafton ST, Sumi SM, Stimac GK et al (1991) Comparison of postmortem magnetic resonance imaging and neuropathologic findings in the cerebral white matter. Arch Neurol 48:293-298
24. van Swieten JC, van den Hout JH, van Ketel BA et al (1991) Periventricular lesions in the white matter on magnetic resonance imaging in the elderly. A morphometric correlation with arteriolosclerosis and dilated perivascular spaces. Brain 114:761-774
25. Haller S, Kovari E, Herrmann FR et al (2013) Do brain T2/FLAIR white matter hyperintensities correspond to myelin loss in normal aging? A radiologic-neuropathologic correlation study. Acta Neuropathologica Commun 1:14
26. Topakian R, Barrick TR, Howe FA et al (2010) Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry 81:192-197
27. de Groot JC, de Leeuw FE, Oudkerk M et al (2000) Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 57:1071-1076
28. Greenberg SM, Vernooij MW, Cordonnier C et al (2009) Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 8:165-174
29. Goos JD, van der Flier WM, Knol DL et al (2011) Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. Stroke 42:1894-1900
30. Cordonnier C, van der Flier WM, Sluimer JD et al (2006) Prevalence and severity of microbleeds in a memory clinic setting. Neurology 66:1356-1360
31. Cordonnier C, Al-Shahi Salman R, Wardlaw J (2007) Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain 130:1988-2003
32. Nandigam RN, Viswanathan A, Delgado P et al (2009) MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol 30:338-343
33. Ayaz M, Boikov AS, Haacke EM et al (2010) Imaging cerebral microbleeds using susceptibility weighted imaging: one step toward detecting vascular dementia. J Magn Reson Imaging 31:142-148
34. Kirsch W, McAuley G, Holshouser B et al (2009) Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. J Alzheimers Dis 17:599-609
35. Haller S, Bartsch A, Nguyen D et al (2010) Cerebral microhemorrhage and iron deposition in mild cognitive impairment: susceptibility-weighted MR imaging assessment. Radiology 257:764-773
36. Uetani H, Hirai T, Hashimoto M et al (2013) Prevalence and topography of small hypointense foci suggesting microbleeds on 3T susceptibility-weighted imaging in various types of dementia. AJNR Am J Neuroradiol 34:984-989
37. Gold G, Giannakopoulos P, Herrmann FR et al (2007) Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain 130:2830-2836
38. Fisher M, French S, Ji P et al (2010) Cerebral microbleeds in the elderly: a pathological analysis. Stroke 41:2782-2785
39. Tanskanen M, Makela M, Myllykangas L et al (2012) Intracerebral hemorrhage in the oldest old: a population-based study (vantaa 85+). Front Neurol 3:103
40. Fazekas F, Kleinert R, Roob G et al (1999) Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 20:637-642
41. Schrag M, McAuley G, Pomakian J et al (2010) Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol 119:291-302
42. Tatsumi S, Shinohara M, Yamamoto T (2008) Direct comparison of histology of microbleeds with postmortem MR images: a case report. Cerebrovasc Dis 26:142-146
43. Torosyan N, Silverman DH (2012) Neuronuclear imaging in the evaluation of dementia and mild decline in cognition. Semin Nucl Med 42:415-422
44. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55:306-319
45. Nordberg A (2011) Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther 3:34
46. Clark CM, Schneider JA, Bedell BJ et al (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305:275-283
47. Aizenstein HJ, Nebes RD, Saxton JA et al (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509-1517
48. Chetelat G, Villemagne VL, Pike KE et al (2011) Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 134:798-807
49. Nordberg A, Carter SF, Rinne J et al (2013) A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 40:104-114
50. Rowe CC, Ng S, Ackermann U et al (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718-1725
51. Small GW, Kepe V, Ercoli LM et al (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652-2663
52. Fodero-Tavoletti MT, Okamura N, Furumoto S et al (2011) 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134:1089-1100
53. Cagnin A, Kassiou M, Meikle SR et al (2006) In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurol Scand Suppl 185:107-114
54. Iannaccone S, Cerami C, Alessio M et al (2013) In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord 19:47-52
55. Marcone A, Garibotto V, Moresco RM et al (2012) [(11)C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer's disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. J Alzheimers Dis 31:387-399
56. Kendziorra K, Wolf H, Meyer PM et al (2011) Decreased cerebral alpha4beta2*nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 38:515-525
57. Franceschi M, Anchisi D, Pelati O et al (2005) Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol 57:216-225
58. Nitsch RM, Hock C (2008) Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Neurotherapeutics 5:415-420
59. Duara R, Barker W, Loewenstein D et al (2009) The basis for disease-modifying treatments for Alzheimer's disease: the sixth annual mild cognitive impairment symposium. Alzheimers Dement 5:66-74
60. Holmes C, Boche D, Wilkinson D et al (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-223
61. Lannfelt L, Blennow K, Zetterberg H et al (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7:779-786
62. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183-194
63. Petersen RC, Negash S (2008) Mild cognitive impairment: an overview. CNS Spectr 13:45-53
64. Mariani E, Monastero R, Mecocci P (2007) Mild cognitive impairment: a systematic review. J Alzheimers Dis 12:23-35
65. Forlenza OV, Diniz BS, Nunes PV et al (2009) Diagnostic transitions in mild cognitive impairment subtypes. Int Psychogeriatr 21:1088-1095
66. Mueller SG, Weiner MW, Thal LJ et al (2005) Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 1:55-66
67. Lovestone S, Francis P, Kloszewska I et al (2009) AddNeuroMed - the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci 1180:36-46
68. Ashburner J, Friston KJ (2000) Voxel-based morphometry - the methods. NeuroImage 11:805-821
69. Scahill RI, Schott JM, Stevens JM et al (2002) Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A 99:4703-4707
70. Karas GB, Burton EJ, Rombouts SA et al (2003) A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. NeuroImage 18:895-907
71. Karas GB, Scheltens P, Rombouts SA et al (2004) Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. NeuroImage 23:708-716
72. Karas G, Sluimer J, Goekoop R et al (2008) Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol 29:944-949
73. Chupin M, Gerardin E, Cuingnet R et al (2009) Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus 19:579-587
74. Holland D, Brewer JB, Hagler DJ et al (2009) Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 106:20954-20959
75. Smith SM, Jenkinson M, Johansen-Berg H et al (2006) Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. NeuroImage 31:1487-1505
76. Damoiseaux JS, Smith SM, Witter MP et al (2009) White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp 30:1051-1059
77. Liu Y, Spulber G, Lehtimaki KK et al (2011) Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 32(9):1558-1571
78. Teipel SJ, Meindl T, Grinberg L et al (2011) The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study. Hum Brain Mapp 32(9):1349-1362
79. Teipel SJ, Pogarell O, Meindl T et al (2009) Regional networks underlying interhemispheric connectivity: an EEG and DTI study in healthy ageing and amnestic mild cognitive impairment. Hum Brain Mapp 30:2098-2119
80. Arenaza-Urquijo EM, Bosch B, Sala-Llonch R et al (2011) Specific anatomic associations between white matter integrity and cognitive reserve in normal and cognitively impaired elders. Am J Geriatr Psychiatry 19:33-42
81. Bosch B, Arenaza-Urquijo EM, Rami L et al (2012) Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiol Aging 33:61-74
82. Teipel SJ, Meindl T, Wagner M et al (2010) Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. J Alzheimers Dis 22:507-522
83. Haller S, Nguyen D, Rodriguez C et al (2010) Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data. J Alzheimers Dis 22:315-327
84. O'Dwyer L, Lamberton F, Bokde AL et al (2012) Using support vector machines with multiple indices of diffusion for automated classification of mild cognitive impairment. PLoS One 7:e32441
85. Haller S, Lovblad KO, Giannakopoulos P (2011) Principles of classification analyses in mild cognitive impairment (MCI) and Alzheimer disease. J Alzheimers Dis 26(Suppl 3):389-394
86. Noble WS (2006) What is a support vector machine? Nat Biotechnol 24:1565-1567
87. Plant C, Teipel SJ, Oswald A et al (2010) Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. NeuroImage 50:162-174
88. Misra C, Fan Y, Davatzikos C (2009) Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. NeuroImage 44:1415-1422
89. Fan Y, Batmanghelich N, Clark CM et al (2008) Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. NeuroImage 39:1731-1743
90. Haller S, Missonnier P, Herrmann FR et al (2013) Individual classification of mild cognitive impairment subtypes by support vector machine analysis of white matter DTI. AJNR Am J Neuroradiol 34:283-291
91. Wee CY, Yap PT, Zhang D et al (2012) Identification of MCI individuals using structural and functional connectivity networks. NeuroImage 59:2045-2056
92. Caroli A, Prestia A, Chen K et al (2012) Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med 53:592-600
93. Chen K, Ayutyanont N, Langbaum JB et al (2011) Characterizing Alzheimer's disease using a hypometabolic convergence index. NeuroImage 56:52-60
94. Garibotto V, Montandon ML, Viaud CT et al (2013) Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med 38:e112-e117
95. Haense C, Herholz K, Jagust WJ et al (2009) Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI). Dement Geriatr Cogn Disord 28:259-266
96. Minoshima S, Frey KA, Koeppe RA et al (1995) A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36:1238-1248
97. Tomlinson BE, Blessed G, Roth M (1968) Observations on the brains of non-demented old people. J Neurol Sci 7:331-356
98. Fotenos AF, Mintun MA, Snyder AZ et al (2008) Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol 65:113-120
99. Garibotto V, Borroni B, Kalbe E et al (2008) Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 71:1342-1349
100. Perneczky R, Haussermann P, Diehl-Schmid J et al (2007) Metabolic correlates of brain reserve in dementia with Lewy bodies: an FDG PET study. Dement Geriatr Cogn Disord 23:416-422
101. Premi E, Garibotto V, Gazzina S et al (2013) Beyond cognitive reserve: behavioural reserve hypothesis in frontotemporal dementia. Behav Brain Res 245:58-62
102. Roe CM, Mintun MA, Ghoshal N et al (2010) Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept. Neurology 75:42-48
103. Vemuri P, Weigand SD, Przybelski SA et al (2011) Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain 134:1479-1492